```
     FILE 'REGISTRY' ENTERED AT 11:23:54 ON 07 JUN 2007
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           48 S L2 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 11:24:57 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:27:12 ON 07 JUN 2007
L4          538 S L3
L5           98 S L3/THU

     FILE 'STNGUIDE' ENTERED AT 11:27:18 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:27:47 ON 07 JUN 2007
L6        13048 S (BLADDER OR (URINARY TRACT) OR URINARY OR UROLOGICAL)(3A)(CAN
L7            6 S L4 AND L6
L8            6 S L5 AND L6
L9            4 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10           4 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'HCAPLUS' ENTERED AT 11:33:04 ON 07 JUN 2007
L11      756337 S (CANCER OR TUMOR OR NEOPLAS?)
L12           4 S L4 AND L9
L13           4 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 11:33:10 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:33:32 ON 07 JUN 2007
L14          57 S L4 AND L11
L15          22 S L14 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.63       0.63

FILE 'REGISTRY' ENTERED AT 11:23:54 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JUN 2007  HIGHEST RN 936692-95-4
DICTIONARY FILE UPDATES:   6 JUN 2007  HIGHEST RN 936692-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10817449chalconemarkush.str
```





chain nodes :
7 8 9 10 17 18 19 20 21 22 23 24 25 27 28 30 31 32 33 34 35
37 38 40 41 42 43 47
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
1-20 2-47 3-19 4-31 5-18 6-7 7-8 7-9 9-10 9-32 10-11 10-33 12-17 13-38
14-37 15-35 16-34 18-41 19-42 20-43 21-22 22-23 22-24 24-25 24-30 25-27
25-28 37-40

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-20 2-47 3-19 5-18 7-8 14-37 18-41 19-42 20-43 21-22 22-23 37-40
exact bonds :
4-31 6-7 7-9 9-10 9-32 10-11 10-33 12-17 13-38 15-35 16-34 22-24 24-25
24-30 25-27 25-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:H,CH3

G2:H,CH3

G3:H,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS
32:CLASS
33:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS 40:CLASS 41:CLASS 42:CLASS
43:CLASS 47:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:24:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 308 TO ITERATE

100.0% PROCESSED 308 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5108 TO 7212
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d l2 scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propen-1-one, 1-[2,6-dihydroxy-4-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)-
MF C21 H22 O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propen-1-one, 1-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxyphenyl)-, (2E)- (9CI)
MF C23 H26 O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l2 sss full
FULL SEARCH INITIATED 11:24:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6923 TO ITERATE

100.0% PROCESSED 6923 ITERATIONS 48 ANSWERS
SEARCH TIME: 00.00.01

L3 48 SEA SSS FUL L1

=> file stnguide
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	173.18

FILE 'STNGUIDE' ENTERED AT 11:24:57 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	173.42

FILE 'HCAPLUS' ENTERED AT 11:27:12 ON 07 JUN 2007

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 6 Jun 2007 (20070606/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3

L4          538 L3

=> s l3/thu

            538 L3
         897599 THU/RL
L5           98 L3/THU
                (L3 (L) THU/RL)

=> s (bladder or (urinary tract) or urinary or urological)(3a)(cancer or tumor or
neoplas?))

UNMATCHED RIGHT PARENTHESIS 'NEOPLAS?))'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l4 and l6

L6 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l5 and l6

L6 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l7 and (PY<2004 or AY<2004 or PRY<2004)

L7 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l8 and (PY<2004 or AY<2004 or PRY<2004)

L8 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).
```

```
=> file stnguide

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.60     176.02

FILE 'STNGUIDE' ENTERED AT 11:27:18 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun  4, 2007 (20070604/UP).

=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.06     176.08

FILE 'HCAPLUS' ENTERED AT 11:27:47 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007  VOL 146 ISS 24
FILE LAST UPDATED: 6 Jun 2007  (20070606/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s (bladder or (urinary tract) or urinary or urological)(3a)(cancer or tumor or
neoplas?)

         36840 BLADDER
        128920 URINARY
        139549 TRACT
          9034 URINARY TRACT
                 (URINARY(W)TRACT)
        128920 URINARY
           330 UROLOGICAL
        317785 CANCER
        409972 TUMOR
        495713 NEOPLAS?
L6       13048 (BLADDER OR (URINARY TRACT) OR URINARY OR UROLOGICAL)(3A)(CANCER
               OR TUMOR OR NEOPLAS?)

=> s l4 and l6

L7            6 L4 AND L6
```

```
=> s l5 and l6

L8            6 L5 AND L6

=> s l7 and (PY<2004 or AY<2004 or PRY<2004)

      23932693 PY<2004
       4727489 AY<2004
       4203849 PRY<2004
L9            4 L7 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l8 and (PY<2004 or AY<2004 or PRY<2004)

      23932693 PY<2004
       4727489 AY<2004
       4203849 PRY<2004
L10           4 L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.60     178.68

FILE 'STNGUIDE' ENTERED AT 11:27:57 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun  4, 2007 (20070604/UP).

=> d l8 1-6 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L8   ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Carotenoids, carotenoid analogs, or carotenoid derivatives for the
     treatment of proliferative disorders

L8   ANSWER 2 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in
     Bladder Cancer Cells by Involvement of Bax
     Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and
     Suppresses Tumor Growth in Mice

L8   ANSWER 3 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Chalcone and flavone compounds for the treatment of bladder and urinary
     tract cancers

L8   ANSWER 4 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Peptidomimetic modulators of cell adhesion

L8   ANSWER 5 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Peptidomimetic modulators of cell adhesion

L8   ANSWER 6 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Peptidomimetic modulators of cell adhesion


=> d l8 1-6 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y
```

L8 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivs. I [R1, R2 = R10-R17; R3 = H, Me; R4 = H, Me; R5 = H, OH, OR6, wherein at least one R5 = OR6; R6 = alkyl, aryl, alkyl-N(R7)2, aryl-N(R7)2, alkyl-N+(R7)3, aryl-N+(R7)3, alkyl-CO2R7, aryl-CO2R7, alkyl-CO2-, aryl-CO2-, OC(:O)R8, P(O)(OR8)2, S(O)(OR2)2, amino acid, peptide, carbohydrate,C(O)(CH2)nCO2R9, nucleoside, co-antioxidant; R8 = H, alkyl, aryl, CH2Ph, co-antioxidant; R9 = H, alkyl, aryl, P(O)(OR8)2, S(O)(OR8)2,amino acid, peptide, carbohydrate, nucleoside, co-antioxidant; n = 1 - 9]. Thus, lutein diphosphate tetrasodium salt (II) was prepared from lutein, via phosphorylation with IP(:O)(OCH2Ph)2 in CH2Cl2 containing pyridine, deesterification with BrSiMe3 in CH2Cl2 containing N,O-bis(trimethylsilyl)acetamide, and salt formation with NaOMe in MeOH. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced. The superoxide anion activity of II was determined using EPR spectroscopy.
AN 2006:976672 HCAPLUS <<LOGINID::20070607>>
DN 145:356957
TI Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
IN Lockwood, Samuel F.; Nadolski, Geoff; Frey, Dean Allen; Mclaws, Mark; Burdick, David
PA Hawaii Biotech, Inc., USA
SO PCT Int. Appl., 119pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006099015	A2	20060921	WO 2006-US8363	20060309
	WO 2006099015	A3	20061221		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006276372	A1	20061207	US 2006-372353	20060309
PRAI	US 2005-659983P	P	20050309		

OS MARPAT 145:356957

L8 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice
AB Consumption of the traditional kava preparation was reported to correlate with low and uncustomary gender ratios (more cancer in women than men) of cancer incidences in three kava-drinking countries: Fiji, Vanuatu, and Western Samoa. We have identified flavokawain A, B, and C but not the major kavalactone, kawain, in kava exts. as causing strong antiproliferative and apoptotic effect in human bladder cancer cells. Flavokawain A results in a significant loss of mitochondrial membrane potential and release of cytochrome c into the cytosol in an invasive bladder cancer cell line T24. These effects of flavokawain A are accompanied by a time-dependent decrease in Bcl-xL, a decrease in the association of Bcl-xL to Bax, and an increase in the active form of Bax protein. Using the primary mouse embryo fibroblasts Bax knockout and wild-type cells as well as a Bax inhibitor peptide derived from the Bax-binding domain of Ku70, we showed that Bax protein was, at least in part, required for the apoptotic effect of flavokawain A. In addition, flavokawain A down-regulates the expression of X-linked inhibitor of apoptosis and survivin. Because both X-linked inhibitor of apoptosis and survivin are main factors for apoptosis resistance and are overexpressed in bladder tumors, our data suggest that flavokawain A may have a dual efficacy in induction of apoptosis preferentially in bladder tumors. Finally, the anticarcinogenic effect of flavokawain A was evident in its inhibitory growth of bladder tumor cells in a nude mice model (57% of inhibition) and in soft agar.
AN 2005:328854 HCAPLUS <<LOGINID::20070607>>
DN 142:475540
TI Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice
AU Zi, Xiaolin; Simoneau, Anne R.
CS Department of Urology and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA
SO Cancer Research (2005), 65(8), 3479-3486
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcone and flavone compounds for the treatment of bladder and urinary tract cancers
AB The invention discloses compns. of matter and methods wherein chalcone and flavone derivs. are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compds. of the invention include 2'-hydroxy-4,4',6'-trimethoxychalcone (Flavokawain A).
AN 2004:1127078 HCAPLUS <<LOGINID::20070607>>
DN 142:49211
TI Chalcone and flavone compounds for the treatment of bladder and urinary tract cancers
IN Zi, Xiolin; Simoneau, Anne R.
PA The Regents of the University of California, USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004259813	A1	20041223	US 2004-817449	20040401
PRAI	US 2003-459495P	P	20030401		

OS MARPAT 142:49211

L8 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
AN 2004:20322 HCAPLUS <<LOGINID::20070607>>
DN 140:87658
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PA Can.
SO U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004006011	A1	20040108	US 2003-425557	20030428
	US 6031072	A	20000229	US 1997-893534	19970711
	US 6326352	B1	20011204	US 2000-507102	20000217
	US 2002168761	A1	20021114	US 2001-769145	20010124
	US 2002151475	A1	20021017	US 2001-6982	20011204
	US 6914044	B2	20050705		
PRAI	US 1996-21612P	P	19960712		
	US 1997-893534	A1	19970711		
	US 2000-491078	B2	20000124		
	US 2000-507102	A1	20000217		
	US 2001-769145	B2	20010124		
	US 2001-6982	A2	20011204		

OS MARPAT 140:87658

L8 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
AN 2002:869496 HCAPLUS <<LOGINID::20070607>>
DN 137:363033
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 15

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------      ----   --------    --------------------   --------
PI   US 2002168761         A1    20021114    US 2001-769145         20010124
     US 2004058864         A1    20040325    US 2003-412701         20030410
     US 2004006011         A1    20040108    US 2003-425557         20030428
PRAI US 2000-491078        A2    20000124
     US 1996-21612P        P     19960712
     US 1997-893534        A1    19970711
     US 2000-507102        A1    20000217
     US 2001-769145        B1    20010124
     US 2001-6982          A2    20011204
OS   MARPAT 137:363033

L8   ANSWER 6 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Peptidomimetic modulators of cell adhesion
AB   Peptidomimetics of cyclic peptides, and compns. comprising such
     peptidomimetics are provided.  The peptidomimetics have a
     three-dimensional structure that is substantially similar to a
     three-dimensional structure of a cyclic peptide that comprises a cadherin
     cell adhesion recognition sequence HAV.  Methods for using such
     peptidomimetics for modulating cadherin-mediated cell adhesion in a
     variety of contexts are also provided.
AN   2001:545724  HCAPLUS <<LOGINID::20070607>>
DN   135:147398
TI   Peptidomimetic modulators of cell adhesion
IN   Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang;
     Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PA   Adherex Technologies, Inc., Can.
SO   PCT Int. Appl., 416 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 15
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   WO 2001053331         A2    20010726    WO 2001-US2508         20010124
     WO 2001053331         A3    20020711
     WO 2001053331         A9    20021031
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-491078        A     20000124
OS   MARPAT 135:147398


=> d his

     (FILE 'HOME' ENTERED AT 11:22:04 ON 07 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 11:23:54 ON 07 JUN 2007
L1             STRUCTURE UPLOADED
L2               2 S L1
L3              48 S L2 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 11:24:57 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:27:12 ON 07 JUN 2007
L4             538 S L3
L5              98 S L3/THU
```

```
     FILE 'STNGUIDE' ENTERED AT 11:27:18 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:27:47 ON 07 JUN 2007
L6         13048 S (BLADDER OR (URINARY TRACT) OR URINARY OR UROLOGICAL)(3A)(CAN
L7             6 S L4 AND L6
L8             6 S L5 AND L6
L9             4 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10            4 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 11:27:57 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:28:19 ON 07 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 11:28:19 ON 07 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 11:28:29 ON 07 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 11:28:30 ON 07 JUN 2007

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.06     203.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -4.68

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:28:36 ON 07 JUN 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 11:31:20 ON 07 JUN 2007
FILE 'STNGUIDE' ENTERED AT 11:31:20 ON 07 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHEs

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.06     203.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -4.68

=> d l8 4-6 hitstr
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L8    ANSWER 4 OF 6  HCAPLUS  COPYRIGHT 2007 ACS on STN
IT    20621-49-2, 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-
      methoxyphenyl)-
```

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 20621-49-2 HCAPLUS

CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



L8 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 20621-49-2, 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 20621-49-2 HCAPLUS

CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



L8 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 20621-49-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

RN 20621-49-2 HCAPLUS

CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.12     213.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -4.68

FILE 'HCAPLUS' ENTERED AT 11:33:04 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007  VOL 146 ISS 24
FILE LAST UPDATED: 6 Jun 2007  (20070606/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s (cancer or tumor or neoplas?)

        317785 CANCER
        409972 TUMOR
        495713 NEOPLAS?
L11     756337 (CANCER OR TUMOR OR NEOPLAS?)

=> s l4 and l9

L12           4 L4 AND L9

=> s l10 and (PY<2004 or AY<2004 or PRY<2004)

      23932693 PY<2004
       4727489 AY<2004
       4203849 PRY<2004
L13           4 L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.60     215.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -4.68

FILE 'STNGUIDE' ENTERED AT 11:33:10 ON 07 JUN 2007
```

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	215.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

FILE 'HCAPLUS' ENTERED AT 11:33:32 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 6 Jun 2007 (20070606/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4 and l11

L14 57 L4 AND L11

=> s l14 and (PY<2004 or AY<2004 or PRY<2004)

23932693 PY<2004
4727489 AY<2004
4203849 PRY<2004
L15 22 L14 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	218.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

FILE 'STNGUIDE' ENTERED AT 11:33:37 ON 07 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> d l15 1-22 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

L15 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of a new xanthohumol-rich hop product in the brewhouse-fate of xanthohumol during beer production and influence of non specific hop compounds on the bitterness of beer

L15 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Production of hop extracts having prenylated flavonoids with estrogenic and antiproliferative bioactivity

L15 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcone and flavone compounds for the treatment of bladder and urinary tract cancers

L15 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion

L15 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Isolation and potential cancer chemopreventive activities of phenolic compounds of beer

L15 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Phytochemical constituents and cancer chemoprevention

L15 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of hop extracts and use in the prophylaxis and therapy of estrogen deficiency related diseases

L15 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cancer chemopreventive activity of Xanthohumol, a natural product derived from Hop

L15 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Comparative chemical attributes of native North American hop, Humulus lupulus var. lupuloides E. Small

L15 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion

L15 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Analysis of true chalcone synthase from Humulus lupulus L. and biotechnology aspects of medicinal hops

L15 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities

L15 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Studies on the production of a xanthohumol-enriched hops product

L15 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Peptidomimetic modulators of cell adhesion

L15 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes

L15 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro biotransformation of xanthohumol, a flavonoid from hops (Humulus lupulus), by rat liver microsomes

L15 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-F]quinoline, mediated by cDNA-expressed human CYP1A2

L15 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus

L15 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines

L15 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Halogenated Chalcones with High-Affinity Binding to P-Glycoprotein: Potential Modulators of Multidrug Resistance

L15 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Commonly occurring plant flavonoids have estrogenic activity

=> d l15 1-22 ti hitstr
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
IT 6754-58-1, Xanthohumol
RL: FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A; curcuminoid compns. exhibiting synergistic inhibition of cyclooxygenase-2 for treatment of inflammation and related disorders)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of a new xanthohumol-rich hop product in the brewhouse-fate of xanthohumol during beer production and influence of non specific hop

compounds on the bitterness of beer

IT 6754-58-1, Xanthohumol
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(xanthohumol fate during beer production and influence of non specific hop compds. on bitterness of beer)

RN 6754-58-1 HCAPLUS

CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Production of hop extracts having prenylated flavonoids with estrogenic and antiproliferative bioactivity

IT 6754-58-1P, Xanthohumol 115063-39-3P, Desmethylxanthohumol
RL: CPS (Chemical process); NPO (Natural product occurrence); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); USES (Uses)
(production of hop exts. enriched in prenylated flavonoids having estrogenic and antiproliferative bioactivity)

RN 6754-58-1 HCAPLUS

CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 115063-39-3 HCAPLUS

CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcone and flavone compounds for the treatment of bladder and urinary tract cancers
IT 37308-75-1 52077-39-1 64680-84-8
265659-35-6 811419-23-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chalcone and flavone compds. for treatment of bladder and urinary tract cancers)
RN 37308-75-1 HCAPLUS
CN 2-Propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 52077-39-1 HCAPLUS
CN 2-Propen-1-one, 1-(4-hydroxy-2,6-dimethoxyphenyl)-3-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 64680-84-8 HCAPLUS
CN 2-Propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 265659-35-6 HCAPLUS
CN 2-Propen-1-one, 1-[2,6-dihydroxy-4-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 811419-23-5 HCAPLUS
CN 2-Propen-1-one, 1-[4-hydroxy-2,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
IT 20621-49-2, 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 20621-49-2 HCAPLUS
CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



L15 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Isolation and potential cancer chemopreventive activities of phenolic compounds of beer
IT 6754-58-1P, Xanthohumol
RL: BSU (Biological study, unclassified); PRP (Properties); PUR

(Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenolic compds. of beer, isolation, characterization, and potential cancer chemopreventive activities)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Phytochemical constituents and cancer chemoprevention
IT 6754-58-1, Xanthohumol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytochem. constituents and cancer chemoprevention)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of hop extracts and use in the prophylaxis and therapy of estrogen deficiency related diseases
IT 6754-58-1P, Xanthohumol
RL: NPO (Natural product occurrence); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(preparation of hop exts. and use in prophylaxis and therapy of estrogen deficiency related diseases)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cancer chemopreventive activity of Xanthohumol, a natural product derived from Hop
IT 6754-58-1P, Xanthohumol
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(cancer chemopreventive activity of Xanthohumol, a natural product derived from Hop)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Comparative chemical attributes of native North American hop, Humulus lupulus var. lupuloides E. Small
IT 6754-58-1, Xanthohumol 265659-35-6, Xanthogalenol
RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence)
(comparative chemical attributes of native North American hop, Humulus lupulus var. lupuloides E. Small)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 265659-35-6 HCAPLUS
CN 2-Propen-1-one, 1-[2,6-dihydroxy-4-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
IT 20621-49-2, 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 20621-49-2 HCAPLUS
CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



L15 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Analysis of true chalcone synthase from Humulus lupulus L. and biotechnology aspects of medicinal hops
IT 6754-58-1, Xanthohumol
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glandular trichome expression of gene chs-H1 chalcone synthase from hops in relation to α-bitter acids and xanthohumol)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities
IT 25515-46-2, Naringenin chalcone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chalcones structure activity studies as antioxidant, estrogenic and antiproliferative agents)
RN 25515-46-2 HCAPLUS
CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Studies on the production of a xanthohumol-enriched hops product
IT 6754-58-1, Xanthohumol
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(xanthohumol-enriched hops product preparation and pilot plant processing design)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
IT 20621-49-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)
RN 20621-49-2 HCAPLUS
CN 2-Propen-1-one, 1-(2,6-dihydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



L15 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes
IT 6754-58-1, Xanthohumol
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro biotransformation of xanthohumol, a flavonoid from hops (Humulus lupulus), by rat liver microsomes
IT 6754-58-1, Xanthohumol
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(biotransformation of xanthohumol by rat liver microsomes)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-F]quinoline, mediated by cDNA-expressed human CYP1A2
IT 6754-58-1, Xanthohumol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(prenylflavonoids inhibit metabolic activation of carcinogenic heterocyclic amine)

RN 6754-58-1 HCAPLUS

CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

TI In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus

IT 6754-58-1, Xanthohumol 115063-39-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of P 450 enzymes by prenylated flavonoids from hops)

RN 6754-58-1 HCAPLUS

CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 115063-39-3 HCAPLUS

CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines
IT 6754-58-1, Xanthohumol 115063-39-3
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiproliferative and cytotoxic effects of prenylated flavonoids from hops in human cancer cell lines)
RN 6754-58-1 HCAPLUS
CN 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 115063-39-3 HCAPLUS
CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Halogenated Chalcones with High-Affinity Binding to P-Glycoprotein: Potential Modulators of Multidrug Resistance
IT 25515-46-2 137225-57-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of halogenated chalcones with high-affinity binding to P-glycoprotein)
RN 25515-46-2 HCAPLUS
CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 137225-57-1 HCAPLUS
CN 2-Propen-1-one, 3-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L15 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Commonly occurring plant flavonoids have estrogenic activity
IT 73692-50-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(estrogenic activity of)
RN 73692-50-9 HCAPLUS
CN 2-Propen-1-one, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)- (9CI) (CA INDEX NAME)



=> d l15 4 10 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chalcone and flavone compounds for the treatment of bladder and urinary tract cancers
AB The invention discloses compns. of matter and methods wherein chalcone and flavone derivs. are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compds. of the invention include 2'-hydroxy-4,4',6'-trimethoxychalcone (Flavokawain A).
AN 2004:1127078 HCAPLUS <<LOGINID::20070607>>
DN 142:49211
TI Chalcone and flavone compounds for the treatment of bladder and urinary

tract cancers
IN Zi, Xiolin; Simoneau, Anne R.
PA The Regents of the University of California, USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004259813	A1	20041223	US 2004-817449	20040401 <--
PRAI US 2003-459495P	P	20030401 <--		

OS MARPAT 142:49211

L15 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Comparative chemical attributes of native North American hop, Humulus lupulus var. lupuloides E. Small
AB The genetic diversity of 159 representative genotypes of native hop (Humulus lupulus var. lupuloides E. Small, Cannabaceae) from 34 selected populations was assessed by relative magnitudes and ranges of alpha acids (AA), beta acids (BA), and the cohumulone (CoH) component of alpha acids, with reference to temporal changes between 1989-1990 and 2001, and to the same attributes in American and European hop cultivars, principally H. lupulus var. lupulus L. Chemical profiles of these genotypes were generated by high pressure liquid chromatog. (HPLC) of methanol exts. from their processed samples (cones). The alpha ratio (AR, alpha acids / alpha+beta acids) measured the degree to which alpha acids predominated in cone exts. Synchronous ranges of AR and CoH were also selected for graphic portrayals of native hop genotypic diversity. Cones sampled and analyzed from eight populations that were accessible in both 1989 and 2001 were distinct in chemical attributes, indicating a succession of genotypes, and suggesting temporal cycling of H. lupulus var.lupuloides germplasm. The principal distinctions between the two sub-species were a markedly higher proportion of CoH (38-88% vs. 19-41%) in alpha acids of H. l. var. lupuloides, and generally higher concns. of AA in cultivars of both American and European com. hop cultivars, predominantly H. lupulus var. lupulus. All of the 159 native hop genotypes also contained detectable levels of xanthohumol and xanthogalenol, prenylflavonoids recently reported to have mammalian anti-cancer activity. Some native genotypes had previously exhibited natural repellence of insect and mite pests; thus H. lupulus var. lupuloides germplasm offers a diverse resource of underutilized and yet undefined biochems.
AN 2002:895378 HCAPLUS <<LOGINID::20070607>>
DN 138:268361
TI Comparative chemical attributes of native North American hop, Humulus lupulus var. lupuloides E. Small
AU Hampton, Richard; Nickerson, Gail; Whitney, Peggy; Haunold, Alfred
CS Horticultural Crops Research Unit, USDA-ARS, Corvallis, OR, 97330, USA
SO Phytochemistry (Elsevier) (2002), 61(7), 855-862
CODEN: PYTCAS; ISSN: 0031-9422
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l15 5 6 7 8 9 11 14 19 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion

AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
AN 2004:20322 HCAPLUS <<LOGINID::20070607>>
DN 140:87658
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PA Can.
SO U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004006011	A1	20040108	US 2003-425557	20030428 <--
	US 6031072	A	20000229	US 1997-893534	19970711 <--
	US 6326352	B1	20011204	US 2000-507102	20000217 <--
	US 2002168761	A1	20021114	US 2001-769145	20010124 <--
	US 2002151475	A1	20021017	US 2001-6982	20011204 <--
	US 6914044	B2	20050705		
PRAI	US 1996-21612P	P	19960712 <--		
	US 1997-893534	A1	19970711 <--		
	US 2000-491078	B2	20000124 <--		
	US 2000-507102	A1	20000217 <--		
	US 2001-769145	B2	20010124 <--		
	US 2001-6982	A2	20011204 <--		

OS MARPAT 140:87658

L15 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Isolation and potential cancer chemopreventive activities of phenolic compounds of beer
AB Beer contains a variety of phenolic compds. During the brewing process, some of these compds. are removed by polyvinylpolypyrrolidone (PVPP) to prevent haze formation. We have analyzed the phytochem. composition of a PVPP residue as well as of unstabilized beer and isolated a total of 51 compds. Eight structures were identified as novel, i.e., 2-(4'-hydroxyphenyl)-3,5-dihydroxybenzoic acid (6), 2'-(4''-hydroxyphenyl)isoferulic acid ester (12), 1,2,5,7-tetrahydroxyanthraquinone (23) and 4,7-dihydroxy-5-(2',4',6'-trihydroxyphenyl)-indan-1,2-dione (24) from the PVPP residue, and catechin-7-O-β-(6''-O-nicotinoyl)-β-D-glucopyranoside (41), ent-epigallo-catechin-(4α →8, 2α →O→7)catechin (44), ent-epigallocatechin (4α →6, 2α →O→7)catechin (45) and 2,3-cis-3,4-trans-2-[2,3-trans-3,3',4',5,7-pentahydroxyflavan-8-yl]-4-(3,4-dihydroxyphenyl)3,5,7-trihydroxybenzopyran (46) from the unstabilized beer. Most of the compds. were tested for potential cancer chemopreventive activities in in vitro test systems detecting a modulation of carcinogen metabolism (inhibition of phase 1 cytochrome P 450 1A (Cyp1A) activity, induction of NAD(P)H:quinone oxidoreductase (QR) activity) and anti-inflammatory mechanisms (inhibition of lipopolysaccharide (LPS)-mediated induction of inducible nitric oxide synthase (iNOS), inhibition of cyclooxygenase 1 (Cox-1) activity). 1,2,5,7-Tetrahydroxyanthraquinone (23) and xanthohumol (25), a prenylated chalcone derived from hop, were identified as the most potent compds. and were addnl. tested for inhibition of chemical-induced preneoplastic lesions in an ex vivo mouse mammary gland organ culture model (MMOC). Importantly, both agents inhibited lesion formation with halfmaximal inhibitory concns. (IC50) of 0.1 and 0.02 μM, resp. Our results demonstrate that beer is

an interesting source of potential cancer chemopreventive agents and should be further investigated with this respect.
AN 2003:1003225 HCAPLUS <<LOGINID::20070607>>
DN 140:180519
TI Isolation and potential cancer chemopreventive activities of phenolic compounds of beer
AU Gerhaeuser, C.; Alt, A. P.; Klimo, K.; Knauft, J.; Frank, N.; Becker, H.
CS Abteilung Toxikologie und Krebsrisikofaktoren, Deutsches Krebsforschungszentrum (DKFZ), Abteilung Toxikologie und Krebsrisikofaktoren, Heidelberg, 69120, Germany
SO Phytochemistry Reviews (2003), Volume Date 2002, 1(3), 369-377
CODEN: PRHEBS; ISSN: 1568-7767
PB Kluwer Academic Publishers
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Phytochemical constituents and cancer chemoprevention
AB A review with 29 refs. on phytochem. constituents and cancer chemoprevention with subdivision headings: (1) flavonoids; tea polyphenols; (3) carotenoids; (4) monoterpenoids; (5) organosulfur compds.; (6) isothiocyanates; (7) phyto-estrogens; other compds.; and (9) conclusion.
AN 2003:340781 HCAPLUS <<LOGINID::20070607>>
DN 139:345056
TI Phytochemical constituents and cancer chemoprevention
AU Lu, Zhiqiang; Lou, Hongxiang
CS School of Pharmacy, Shandong University, Jinan, 250012, Peop. Rep. China
SO Zhongcaoyao (2002), 33(6), 563-566
CODEN: CTYAD8; ISSN: 0253-2670
PB Zhongcaoyao Zazhi Bianjibu
DT Journal; General Review
LA Chinese

L15 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of hop extracts and use in the prophylaxis and therapy of estrogen deficiency related diseases
AB The invention relates to novel hop exts. with an increased content in prenylated chalcones and flavones. The invention also relates to a method for the production , to pharmaceutical prepns. comprising such hop exts. and to the use of the hop exts. in the prophylaxis and therapy of conditions that are caused by estrogen deficiency or by a dysregulation of the sex hormone metabolism
AN 2003:133407 HCAPLUS <<LOGINID::20070607>>
DN 138:175812
TI Preparation of hop extracts and use in the prophylaxis and therapy of estrogen deficiency related diseases
IN Erdelmeier, Clemens; Koch, Egon
PA Willmar Schwabe Gmbh & Co., Germany
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003014287	A1	20030220	WO 2002-EP8943	20020809 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,

UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE	10139479	A1	20030227	DE 2001-10139479	20010810 <--
AU	2002324044	A1	20030224	AU 2002-324044	20020809 <--
EP	1414937	A1	20040506	EP 2002-758454	20020809 <--
EP	1414937	B1	20050608		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN	1541262	A	20041027	CN 2002-815697	20020809 <--
JP	2004537604	T	20041216	JP 2003-519220	20020809 <--
AT	297460	T	20050615	AT 2002-758454	20020809 <--
ES	2240787	T3	20051016	ES 2002-2758454	20020809 <--
US	2005042318	A1	20050224	US 2004-486390	20040908 <--
PRAI DE	2001-10139479	A	20010810 <--		
WO	2002-EP8943	W	20020809 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Cancer chemopreventive activity of Xanthohumol, a natural product derived from Hop

AB Characterization and use of effective cancer chemopreventive agents have become important issues in public health-related research. Aiming to identify novel potential chemopreventive agents, we have established an interrelated series of bioassay systems targeting mol. mechanisms relevant for the prevention of tumor development. We report anticarcinogenic properties of Xanthohumol (XN), a prenylated chalcone from Hop (Humulus lupulus L.) with an exceptional broad spectrum of inhibitory mechanisms at the initiation, promotion, and progression stage of carcinogenesis. Consistent with anti-initiating potential, XN potently modulates the activity of enzymes involved in carcinogen metabolism and detoxification. Moreover, XN is able to scavenge reactive oxygen species, including hydroxyl- and peroxyl radicals, and to inhibit superoxide anion radical and nitric oxide production As potential antitumor-promoting mechanisms, it demonstrates anti-inflammatory properties by inhibition of cyclooxygenase-1 and cyclooxygenase-2 activity and is antiestrogenic without possessing intrinsic estrogenic potential. Antiproliferative mechanisms of XN to prevent carcinogenesis in the progression phase include inhibition of DNA synthesis and induction of cell cycle arrest in S phase, apoptosis, and cell differentiation. Importantly, XN at nanomolar concns. prevents carcinogen-induced preneoplastic lesions in mouse mammary gland organ culture. Because XN is easily cyclized to the flavanone isoxanthohumol, activities of both compds. were compared throughout the study. Together, our data provide evidence for the potential application of XN as a novel, readily available chemopreventive agent, and clin. investigations are warranted once efficacy and safety in animal models have been established.

AN 2003:69747 HCAPLUS <<LOGINID::20070607>>
DN 139:143483

TI Cancer chemopreventive activity of Xanthohumol, a natural product derived from Hop

AU Gerhauser, Clarissa; Alt, Axel; Heiss, Elke; Gamal-Eldeen, Amira; Klimo, Karin; Knauft, Jutta; Neumann, Isabell; Scherf, Hans-Rudolf; Frank, Norbert; Bartsch, Helmut; Becker, Hans
CS Deutsches Krebsforschungszentrum, Abteilung Toxikologie und Krebsrisikofaktoren, Heidelberg, 69120, Germany

SO Molecular Cancer Therapeutics (2002), 1(11), 959-969
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal
LA English

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Peptidomimetic modulators of cell adhesion
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
AN 2002:869496 HCAPLUS <<LOGINID::20070607>>
DN 137:363033
TI Peptidomimetic modulators of cell adhesion
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PA Can.
SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168761	A1	20021114	US 2001-769145	20010124 <--
	US 2004058864	A1	20040325	US 2003-412701	20030410 <--
	US 2004006011	A1	20040108	US 2003-425557	20030428 <--
PRAI	US 2000-491078	A2	20000124 <--		
	US 1996-21612P	P	19960712 <--		
	US 1997-893534	A1	19970711 <--		
	US 2000-507102	A1	20000217 <--		
	US 2001-769145	B1	20010124 <--		
	US 2001-6982	A2	20011204 <--		

OS MARPAT 137:363033

L15 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Studies on the production of a xanthohumol-enriched hops product
AB A review. Current pharmacol. studies show pos. aspects for xanthohumol and related prenylflavonoids of hops for possible prevention of osteoporosis, arteriosclerosis, and cancer. The xanthohumol content in hops (0.2-1.1%) is a varietal characteristic. Hop extraction with ethanol followed by fractionation of the pure resin extract with supercrit. CO2 can partially sep. α- and β-acids from xanthohumol and yield a hop product enriched in xanthohumol. The xanthohumol content can be ≤10%, depending on the hop variety used. A pilot plant for xanthohumol-enriched hop product preparation was evaluated. The production process used a new technique of high-pressure spray extraction A design for a continuous hop extraction plant using this technique is presented. The demand for xanthohumol-enriched hop products could increase to be used as a beneficial ingredient in foods or as a nutraceutical. Brewing trials with the xanthohumol-enriched hop product showed its possible applications in beer production
AN 2001:633130 HCAPLUS <<LOGINID::20070607>>
DN 136:19171
TI Studies on the production of a xanthohumol-enriched hops product
AU Biendl, Martin; Eggers, R.; Czerwonatis, N.; Mitter, W.
CS Hallertauer Hopfenveredelungsgesellschaft m.b.H., Hallertau, Germany
SO Cerveza y Malta (2001), 38(150), 25-27,29
CODEN: CEMADD; ISSN: 0300-4481
PB Asociacion Espanola de Tecnicos de Cerveza y Malta
DT Journal; General Review
LA Spanish

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus
AB 1. Several unique flavonoid compds. have recently been isolated from hops, Humulus lupulus, and their presence has been detected in beer. Their chemical structures are similar to other plant-derived compds., many present in the human diet, that have been shown to have cancer chemopreventive properties due, in part, to inhibition of cytochrome P 450 enzymes that activate carcinogens. Addnl., preliminary studies have shown these flavonoids (at 100 μM) to be inhibitory of P 450-mediated activation reactions in a variety of in vitro systems. Thus, the in vitro effects of these phytochems. on cDNA-expressed human CYP1A1, CYP1B1, CYP1A2, CYP3A4 and CYP2E1 were currently examined by the use of diagnostic substrates and the carcinogen AFB1. 2. At 10 μM, the prenylated chalcone, xanthohumol (XN), almost completely inhibited the 7-ethoxyresorufin O-deethylase (EROD) activity of CYP1A1. At the same concentration, other hop flavonoids decreased the EROD activity by 90.8-27.0%. 3. At 10 μM, XN completely eliminated CYP1B1 EROD activity, whereas the other hop flavonoids showed varying degrees of inhibitory action ranging from 99.3 to 1.8%. 4. In contrast, the most effective inhibitors of CYP1A2 acetanilide 4-hydroxylase activity were the two prenylated flavonoids, 8-prenylnaringenin (8PN) and isoxanthohumol (IX), which produced > 90% inhibition when added at concns. of 10 μM. 5. CYP1A2 metabolism of the carcinogen AFB1 was also inhibited by IX and 8PN as shown by decreased appearance of dihydrodiols and AFM1 as analyzed by hplc. IX and 8PN also decreased covalent binding of radiolabeled AFB1 to microsomal protein in a concomitant manner. 6. XN, IX and 8PN, however, were poor inhibitors of CYP2E1 and CYP3A4 as measured by their effect on chorzoxazone hydroxylase and nifedipine oxidase activities resp. 7. These results suggest that the hop flavonoids are potent and selective inhibitors of human cytochrome P 450 and warrant further in vivo investigations.
AN 2000:367565 HCAPLUS <<LOGINID::20070607>>
DN 133:144880
TI In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus
AU Henderson, M. C.; Miranda, C. L.; Stevens, J. F.; Deinzer, M. L.; Buhler, D. R.
CS Departments of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA
SO Xenobiotica (2000), 30(3), 235-251
CODEN: XENOBH; ISSN: 0049-8254
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT